Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07226297 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D)

StatusEnrolling by Invitation
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Charcot-Marie-Tooth disease type 2D (CMT2D) due to a pathogenic, de novo deletion mutation in GARS1
Trial Details
NCT Number NCT07226297
Lead Sponsor n-Lorem Foundation
Collaborators: The University of Texas Health Science Center, Houston
Conditions
(from sponsor)		 Charcot-Marie-Tooth Disease Type 2D
Related terms Charcot-Marie-Tooth disease, Type 2D
Enrollment 1 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov